Exelixis

(NASDAQ) EXEL

Current Price$55.62

Market Cap$13.96B

Since IPO (2000)+266%

5 Year+231%

1 Year+26%

1 Month+5%

Exelixis last closing stock price
Metric	Price	Date
Last close	USD 55.55	2026-07-15

Exelixis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-1%	USD 56.11	2026-07-08
1 month	+4.81%	USD 53.00	2026-06-15
3 month	+25.17%	USD 44.38	2026-04-16
Year to date	+26.74%	USD 43.83	2025-12-31
1 year	+26.08%	USD 44.06	2025-07-15
3 year	+186.49%	USD 19.39	2023-07-14
5 year	+230.65%	USD 16.80	2021-07-16
Since inception	+265.76%	USD 15.19	2000-04-11

Exelixis Financials at a Glance

Market Cap

$13.96B

Revenue (TTM)

$2.38B

Net Income (TTM)

$833.42M

EPS (TTM)

$3.02

P/E Ratio

18.41

Dividend

$0.00

Beta (Volatility)

0.62 (Low)

Dividend

$0.00

Beta (Volatility)

0.62 (Low)

Price

$55.62

Volume

2,031,019

Open

$55.55

Price

$55.62

Volume

2,031,019

Open

$55.55

Previous Close

$55.68

Daily Range

$55.29 - $56.75

52-Week Range

$33.76 - $57.57

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

0.62 (Low)

Price

$55.62

Volume

2,031,019

Open

$55.55

Previous Close

$55.68

Daily Range

$55.29 - $56.75

52-Week Range

$33.76 - $57.57

Estimated Earnings Date

Aug 4, 2026

EXEL News

A biotech lab technician using multiple pipettes to load blood samples into test tubes.

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

James HalleyFeb 28, 2026

Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in SPDR S&P Biotech ETF (XBI)

Rachel WarrenFeb 25, 2026

Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

Prosper Junior BakinyFeb 20, 2026

2 Stocks That Could Soar This Year

Prosper Junior BakinyJan 31, 2026

The Ultimate Biotech Stock to Buy With $50 Right Now

Prosper Junior BakinyOct 14, 2025

Page 1

EXEL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Exelixis

Exelixis develops medicines that help people with advanced cancers live longer. Its main drugs treat kidney, liver, and thyroid cancers. These medicines are used by doctors to manage difficult cancer cases.

What’s in the Exelixis Medicine Cabinet?

Cabozantinib Franchise (CABOMETYX, COMETRIQ): Tablets and capsules for advanced kidney, liver, and thyroid cancers; 99% of product revenue in 2024; used by oncologists for patients needing new treatment options.
COTELLIC: Oral drug for advanced melanoma (skin cancer); marketed by Genentech; generates profit share and royalties for Exelixis.
MINNEBRO: Blood pressure medicine for hypertension in Japan; marketed by Daiichi Sankyo; Exelixis receives royalties.
Pipeline Programs: New cancer drugs in clinical trials, including zanzalintinib and several early-stage therapies; aim to treat a wider range of solid tumors.

Growth Moves: The Exelixis Expansion Playbook

Formed global partnerships with Ipsen (Europe, 2016) and Takeda (Japan, 2017) to commercialize cabozantinib outside the U.S.
Launched CABOMETYX in new cancer types and geographies from 2016 to 2024, expanding its market reach.
Entered collaborations with Genentech (COTELLIC) and Daiichi Sankyo (MINNEBRO) to diversify revenue streams.
Expanded research pipeline through licensing deals with companies like Redwood Bioscience and Aurigene Discovery Technologies.
Authorized $500 million stock repurchase program in 2024, following $450 million completed buyback.

What Makes Exelixis Stand Out?

Exelixis controls drug discovery, development, and sales, giving it flexibility and speed. Its main drug, cabozantinib, is a standard treatment for advanced kidney cancer. The company relies on global partners to reach patients outside the U.S. and invests heavily in new cancer therapies.

Five Things You Need to Know

Total revenue was $2.17 billion in 2024, up 18% from 2023.
CABOMETYX made up 99% of product revenue in 2024, rising 11% year-over-year.
Net income reached $521 million in 2024, up 151% from 2023.
Operating cash flow was $700 million in 2024, up 110% from 2023.

Bottom Line

Exelixis has grown by focusing on cancer drugs and expanding through partnerships. Its strong cash flow and pipeline investments support ongoing adaptation in a competitive market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,077

CEO

Michael M. Morrissey, PhD

Website

www.exelixis.com

Headquarters

Alameda, CA 94502, US

EXEL Financials

Key Financial Metrics (TTM)

Gross Margin

96.44%

Operating Margin

39.43%

Net Income Margin

35.08%

Return on Equity

40.21%

Return on Capital

37.36%

Return on Assets

32.13%

Earnings Yield

5.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.96B

Shares Outstanding

251.35M

Volume

2.03M

Avg. Volume

2.73M

Financials (TTM)

Gross Profit

$2.29B

Operating Income

$936.67M

EBITDA

$1.02B

Operating Cash Flow

$924.68M

Capital Expenditure

-$8.26M

Free Cash Flow

$916.41M

Cash & ST Invst.

$777.21M

Total Debt

$169.54M

Exelixis Performance Analysis

Exelixis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,611,062,000	12.3%
2023	2023-12-31	USD 1,830,208,000	13.6%
2024	2024-12-31	USD 2,168,701,000	18.5%
2025	2025-12-31	USD 2,320,126,000	7.0%

Exelixis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-07-04	2.3%
Q3	2025-10-03	5.2%
Q4	2026-01-02	0.2%
Q1	2026-04-03	2.0%

Exelixis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 0.56	-21.7%
2023	2023-12-31	USD 0.65	15.1%
2024	2024-12-31	USD 1.76	172.4%
2025	2025-12-31	USD 2.78	57.7%

Exelixis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-07-04	18.2%
Q3	2025-10-03	7.7%
Q4	2026-01-02	25.7%
Q1	2026-04-03	-10.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$610.81M

+10.0%

Gross Profit

$590.86M

+10.2%

Gross Margin

96.73%

N/A

Market Cap

$13.96B

N/A

Market Cap/Employee

$12.96M

N/A

Employees

1,077

N/A

Net Income

$210.47M

+31.9%

EBITDA

$274.64M

+28.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$777.21M

-24.6%

Total Debt

$169.54M

-9.4%

Accounts Receivable

$328.95M

+16.8%

Inventory

$26.61M

+7.0%

Long Term Debt

$169.54M

-9.4%

Short Term Debt

$0.00

N/A

Return on Assets

32.13%

N/A

Return on Invested Capital

42.14%

N/A

Free Cash Flow

$249.81M

+32.2%

Operating Cash Flow

$251.85M

+19.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ALGNAlign Technology, Inc.

ALGNAlign Technology, Inc.$178.41-1.57%

MDGLMadrigal Pharmaceuticals, Inc.

MDGLMadrigal Pharmaceuticals, Inc.$545.53-0.86%

BBIOBridgeBio Pharma, Inc.

BBIOBridgeBio Pharma, Inc.$80.30-2.86%

BMRNBioMarin Pharmaceutical Inc.

BMRNBioMarin Pharmaceutical Inc.$60.00+1.78%

TECHBio-Techne Corporation

TECHBio-Techne Corporation$71.77+0.41%

HALOHalozyme Therapeutics, Inc.

HALOHalozyme Therapeutics, Inc.$77.54+2.27%

CAICaris Life Sciences, Inc.

CAICaris Life Sciences, Inc.$16.48-5.61%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NUNu Holdings

NUNu Holdings$13.79-0.01%

ATAIAtaiBeckley

ATAIAtaiBeckley$7.15+0.33%

NOKNokia

NOKNokia$10.38-0.08%

ONDSOndas

ONDSOndas$6.65-0.06%

INTCIntel

INTCIntel$96.98-0.06%

PATHUiPath

PATHUiPath$12.03+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.32-0.03%

Questions About EXEL

What is the current price of Exelixis?

Exelixis is trading at $55.68 per share.

What is the 52-week range for Exelixis?

Over the past 52 weeks, Exelixis has traded between $33.76 and $57.57.

How much debt does Exelixis have?

As of the most recent reporting period, Exelixis reported total debt of $169.54M.

How much cash does Exelixis have on hand?

Exelixis reported $163.44M in cash and cash equivalents in its most recent financial results.

What is Exelixis’s dividend yield?

Exelixis does not currently have a dividend yield.

Exelixis

Exelixis Financials at a Glance

EXEL News

5 Best Biotech Stocks for 2026 and How to Invest

Prediction: This Stock Could Double By 2031

Exelixis: A Strong Contender in the Cancer Drug Market

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

How to Invest in SPDR S&P Biotech ETF (XBI)

Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

2 Stocks That Could Soar This Year

The Ultimate Biotech Stock to Buy With $50 Right Now

EXEL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Exelixis

What’s in the Exelixis Medicine Cabinet?

Growth Moves: The Exelixis Expansion Playbook

What Makes Exelixis Stand Out?

Five Things You Need to Know

Bottom Line

EXEL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Exelixis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EXEL

What is the current price of Exelixis?

What is the 52-week range for Exelixis?

How much debt does Exelixis have?

How much cash does Exelixis have on hand?

What is Exelixis’s dividend yield?

Premium Investing Services